Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-05-10
2011-05-10
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S133100, C424S134100, C424S141100, C424S143100, C424S145100, C424S178100, C514S007600, C514S012200, C514S013300, C514S017700, C514S021200
Reexamination Certificate
active
07939490
ABSTRACT:
The present invention is directed to compositions and methods for treating cerebral edema and cell death in neurological conditions characterized by disruption of the architecture of the neurovascular unit with increase in the permeability of the NVU, particularly for treating stroke. One aspect of the present invention relates to a composition comprising an agent that interferes with a TWEAK-mediated signaling pathway. Another aspect of the present invention relates to a method of using a composition which comprises an agent that inhibits Fn14 activity or Fn14 expression for the prevention and/or treatment of cerebral edema and cell death occurring in certain neurological conditions such as cerebral ischemia.
REFERENCES:
patent: 5149655 (1992-09-01), McCabe et al.
patent: 5206152 (1993-04-01), Sukhatme
patent: 5422120 (1995-06-01), Kim
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5919619 (1999-07-01), Tullis
patent: 7169387 (2007-01-01), Rennert
patent: 7482430 (2009-01-01), Wiley
patent: 2006/0240004 (2006-10-01), Burkly et al.
patent: 2009/0053211 (2009-02-01), Lazar et al.
patent: 2009/0068102 (2009-03-01), Burkly et al.
patent: 524968 (1991-10-01), None
patent: 90/11092 (1990-10-01), None
patent: 91/14445 (1991-10-01), None
patent: 92/11033 (1992-07-01), None
patent: 94/23697 (1994-10-01), None
patent: 95/13796 (1995-05-01), None
patent: 99/14346 (1999-03-01), None
patent: WO 00/42073 (2000-07-01), None
patent: 01/29058 (2001-04-01), None
patent: WO 2006/130374 (2006-12-01), None
Ballabh P et al. The blood-brain barrier: an overview. Structure, regulation, and clinical implications. Neurobiology Disease, 2004; 16:1-13.
Chu K et al. Celevoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab. Aug. 2004; 24(8):926-933; abstract only.
Alberts B et al. Molecular Biology of the Cell, Fourth Edition, 2002, Garland Science, p. 129.
International Search Report and Written Opinion, International Patent Application No. PCT/US05/40360, Issued May 8, 2006.
Aggoun-Zouaoui, D., et al., “Ultrastructural Morphology of Neuronal Death Following Reversible Focal Ischemia in the Rat,” Apoptosis, 3:133-141, (1998).
Asahi, M., et al., “Role for Matrix Metalloproteinase 9 After Focal Cerebral Ischemia: Effects of Gene Knockout and Enzyme Inhibition with BB-94,” J. Cereb. Blood Flow and Metab., 20:1681-1689, (2000).
Asahi, M., et al., “Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood-Brain Barrier and White Matter Components After Cerebral Ischemia,” The Journal of Neuroscience, 21(19):7724-7732, (2001).
Backskai, B.J., et al., “The Endocytic Receptor Protein LRP Also Mediates Neuronal Calcium Signaling Via N-Methyl-D-Aspartate Receptors,” PNAS, 97(21):11551-11556, (2000).
Baker, R.N., et al., “The Movement of Exogenous Protein in Experimental Cerebral Edema,” J. Neuropathol. Exp. Neurol., 30:668-679, (1971).
Barber, P.A., et al., “Biochemistry of Ischemic Stroke,” Advances in Neurology, 92:151-164, (2003).
Bolton, S.J., et al., “Loss of the Tight Junction Proteins Occludin and Zonula Occludens-1 from Cerebral Vascular Endothelium During Neutrophil-Induced Blood-Brain Barrier Breakdown In Vivo,” Neuroscience, 86(4):1245-1257, (1998).
Brown, S.A., et al., “The Fn14 Cytoplasmic Tail Binds Tumour-Necrosis-Factor-Receptor-Associated Factors 1, 2, 3, and 5 and Mediates Nuclear Factor-κB Activation,” Biochem. Journal, 371:395-403, (2003).
Carson, M.P., et al., “Microvascular Endothelium and Pericytes: High Yield, Low Passage Cultures,” In Vitro Cell & Dev. Biol., 22(6):344:354, (1986).
Chen, Z., et al., “Brain Capillary Endothelial Cells Express MBEC1, a Protein that is Related to theClostridium perfringensEnterotoxin Receptors,” Laboratory Investigation, 78(3):353-363, (1998).
Chicheportiche, Y., et al., “TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family that Weakly Induces Apoptosis,” The Journal of Biological Chemistry, 272(51):32401-32410, (1997).
Curiel, D.T., et al., “High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes,” Human Gene Therapy, 3:147-154, (1992).
Desplat-Jégo, S., et al., “TWEAK Is Expressed by Glial Cells, Induces Astrocyte Proliferation and Increases EAE Severity,” Journal of Neuroimmunology, 133:116-123, (2002).
Dirnagl, U., et al., “Pathobiology of Ischaemic Stroke: An Integrated View,” Trends Neurosci., 22(9):391-397, (1999).
Dereski, M.O., et al., “The Heterogeneous Temporal Evolution of Focal Ischemic Neuronal Damage in the Rat,” Acta Neuropathol. (Berl.), 85:327-333, (1993).
Donohue, P.J., et al., “TWEAK is an Endothelial Cell Growth and Chemotactic Factor that Also Potentiates FGF-2 and VEGF-A Mitogenic Activity,” Arterioscler. Throm. Vasc. Biol., 23:594-600, (2003).
Feng, S.L.Y., et al., “The Fn14 Immediate-Early Response Gene is Induced During Liver Regeneration and Highly Expressed in Both Human and Murine Hepatocellular Carcinomas,” American Journal of Pathology, 156(4):1253-1261, (2000).
Fischer, D., et al., “Switching Mature Retinal Ganglion Cells to a Robust Growth State In Vivo: Gene Expression and Synergy with RhoA Inactivation,” The Journal of Neuroscience, 24(40):8726-8740, (2004).
Flaris, N.A., et al., “Characterization of Microglia and Macrophages in the Central Nervous System of Rats: Definition of the Differential Expression of Molecules Using Standard and Novel Monoclonal Antibodies in Normal CNS and in Four Models of Parenchymal Reaction,” Glia, 7:34-40, (1993).
Garcia, J.H., et al., “Neuronal Ischemic Injury: Light Microscopy, Ultrastructure and Biochemistry,” Acta Neuropathol. (Berl), 43:85-95, (1978).
Hakim, A.M., “The Cerebral Ischemic Penumbra,” Le Journal Canadien Des Sciences Neurologiques, 14(4):557-559, (1987).
Han, S., et al., “TNF-Related Weak Inducer of Apoptosis Receptor, a TNF Receptor Superfamily Member, Activates NF-κB Through TNF Receptor-Associated Factors,” Biochem. Biophys. Res. Commun., 305:789-796, (2003).
Harada, N. et al., “Pro-Inflammatory Effect of TWEAK/Fn14 Interaction on Human Umbilical Vein Endothelial Cells,” Biochem. Biophys. Res. Commun., 299:488-493, (2002).
Huckett, B., et al., “Evidence for Targeted Gene Transfer by Receptor-Mediated Endocytosis,” Biochem. Pharmacol., 40(2):253-263, (1990).
Jin, L., et al., “Induction of RANTES by TWEAK/Fn14 Interaction in Human Keratinocytes,” The Journal of Investigative Dermatology, 122:1175-1179, (2004).
Kaltschmidt, C., et al., “Constitutive NF-κB Activity in Neurons,” Molecular and Cellular Biology, 14(6):3981-3992, (1994).
Kato, H., et al., “Progressive Expression of Immunomolecules on Activated Microglia and Invading Leukocytes Following Focal Cerebral Ischemia in the Rat,” Brain Research, 734:203-212, (1996).
Kawakita, T., et al., “Functional Expression of TWEAK in Human Hepatocellular Carcinoma: Possible Implication in Cell Proliferation and Tumor Angiogenesis,” Biochem. Biophys. Res. Commun., 318:726-733, (2004).
Kim, S.H., et al., “TWEAK Can Induce Pro-Inflammatory Cytokines and Matrix Metalloproteinase-9 in Macrophages,” . Circ. J., 68:396-399, (2004).
Lee, J.M., et al., “The Changing Landscape of Ischaemic Brain Injury Mechanisms,” Nature, 399:A7-14, (1999).
Lee, Y.B., et al., “Cytokines, Chemokines, and Cytokine Receptors in Human Microglia,” Journal of Neuroscience Research, 69:94-103, (2002).
Lehrmann, E., et al., “Microglia and Macrophages are Major Sources of Locally Produced Transforming Growth Factor-β1 After Transient Middle Cerebral Artery Occlusion in Rats,” Glia, 24:437-448, (1998).
Lynch, C.N., et al.,
Winkles Jeffrey A.
Yepes Manuel S.
Ballard Kimberly A.
DLA Piper (LLP) US
Kemmerer Elizabeth C.
University of Maryland Baltimore
LandOfFree
TWEAK as a therapeutic target for treating central nervous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TWEAK as a therapeutic target for treating central nervous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TWEAK as a therapeutic target for treating central nervous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2673335